IFPA launches first Africa Forum on psoriasis calling for urgent action on overlooked disease
Nairobi event takes place May 7-9 STOCKHOLM, March 30, 2026 /PRNewswire/ --…
Palvella Therapeutics Highlights Continued Progress Across Rare Skin Disease Pipeline with Two Poster Presentations at the 2026 American Academy of Dermatology Annual Meeting
Poster #76954 highlights QTORIN™ rapamycin’s single phase anhydrous gel formulation designed to…
NKGen Biotech to Present Integrated Phase 1 Clinical and Biomarker Analyses for Troculeucel in Alzheimers Disease at AD/PD 2026
March 10, 2026 08:05 ET | Source: NKGen Biotech, Inc. SANTA ANA,…
Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026
Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical…
Harness Therapeutics Nominates HRN001, a First-in-Class Drug Candidate for Huntingtons Disease and Establishes Clinical Advisory Board
HRN001 is a potent and specific antisense oligonucleotide designed to drive controlled…
MerryLife Biomedical Reports Positive Phase 1 Results and Plans for Global Phase 2 Trial for TML-6, an Oral Multi-Targeted Investigational Therapy for Alzheimer’s Disease
TAINAN, Feb. 10, 2026 /PRNewswire/ -- MerryLife Biomedical Inc., a clinical-stage biotechnology…
Role of CathWorks FFRangio for the Assessment of Coronary Artery Disease Now Reinforced by SCAI Expert Opinion
NEWPORT BEACH, Calif., Feb. 3, 2026 /PRNewswire/ -- CathWorks, a global leader…
Press Release: Sanofis Rezurock recommended for EU approval by the CHMP to treat chronic graft-vs-host disease
Sanofi’s Rezurock recommended for EU approval by the CHMP to treat chronic…
Skyhawk Therapeutics Announces Nine Month Interim Results in Patients from its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington’s Disease
Nine-month findings show mean improvement in Composite Unified Huntington's Disease Rating Scale…
FDA Accepts LEQEMBI IQLIK (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimers Disease under Priority Review
If approved, LEQEMBI IQLIK would be the first and only anti-amyloid treatment…
